Nathaniel Gardiner Net Worth

The estimated Net Worth of Nathaniel S. Gardiner is at least $2.74 Million dollars as of 26 February 2024. Mr. Gardiner owns over 5,187 units of Enanta Pharmaceuticals Inc stock worth over $911,284 and over the last 10 years he sold ENTA stock worth over $334,793. In addition, he makes $1,494,230 as Senior Vice President and General Counsel at Enanta Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Gardiner ENTA stock SEC Form 4 insiders trading

Nathaniel has made over 19 trades of the Enanta Pharmaceuticals Inc stock since 2015, according to the Form 4 filled with the SEC. Most recently he exercised 5,187 units of ENTA stock worth $46,631 on 26 February 2024.

The largest trade he's ever made was exercising 6,667 units of Enanta Pharmaceuticals Inc stock on 18 April 2023 worth over $200,010. On average, Nathaniel trades about 1,462 units every 83 days since 2014. As of 26 February 2024 he still owns at least 75,688 units of Enanta Pharmaceuticals Inc stock.

You can see the complete history of Mr. Gardiner stock trades at the bottom of the page.

Nathaniel Gardiner biography

Nathaniel S. Gardiner, J.D., is Senior Vice President and General Counsel of the Company. He has served as our Senior Vice President and General Counsel since May 2014 and has served as our Secretary since 1995. Previously Mr. Gardiner was a corporate and securities law partner for 25 years, most recently at Edwards Wildman Palmer LLP since October 2011, previously at Edwards Angell Palmer & Dodge LLP since November 2005, and before that at Palmer & Dodge LLP, where he represented Enanta and several other biotechnology companies. Mr. Gardiner received his A.B. from Harvard College and his J.D. from the University of Virginia School of Law.

What is the salary of Nathaniel Gardiner?

As the Senior Vice President and General Counsel of Enanta Pharmaceuticals Inc, the total compensation of Nathaniel Gardiner at Enanta Pharmaceuticals Inc is $1,494,230. There are 4 executives at Enanta Pharmaceuticals Inc getting paid more, with Jay Luly having the highest compensation of $4,483,500.

How old is Nathaniel Gardiner?

Nathaniel Gardiner is 66, he's been the Senior Vice President and General Counsel of Enanta Pharmaceuticals Inc since 2014. There are 4 older and 10 younger executives at Enanta Pharmaceuticals Inc. The oldest executive at Enanta Pharmaceuticals Inc is Bruce Carter, 76, who is the Independent Non-Executive Chairman of the Board.

What's Nathaniel Gardiner's mailing address?

Nathaniel's mailing address filed with the SEC is C/O ENANTA PHARMACEUTICALS, INC., 500 ARSENAL STREET, WATERTOWN, MA, 02472.

Insiders trading at Enanta Pharmaceuticals Inc

Over the last 12 years, insiders at Enanta Pharmaceuticals Inc have traded over $72,640,961 worth of Enanta Pharmaceuticals Inc stock and bought 354,891 units worth $5,071,651 . The most active insiders traders include Jay R. Luly, V Life Science Ventures Gmb..., and Yat Sun Or. On average, Enanta Pharmaceuticals Inc executives and independent directors trade stock every 26 days with the average trade being worth of $285,155. The most recent stock trade was executed by Scott T. Rottinghaus on 11 July 2024, trading 11,945 units of ENTA stock currently worth $190,762.

What does Enanta Pharmaceuticals Inc do?

enanta pharmaceuticals is a research and development-focused biotechnology company that uses its robust chemistry-driven approach and drug discovery capabilities to create small molecule drugs for viral infections and liver diseases. enanta is discovering, and in some cases developing, novel inhibitors designed for use against the hepatitis c virus (hcv). these inhibitors include members of the direct acting antiviral (daa) inhibitor classes – protease (partnered with abbvie), ns5a, and nucleotide polymerase – as well as a host-targeted antiviral (hta) inhibitor class targeted against cyclophilin. enanta’s lead protease inhibitor, paritaprevir, is part of abbvie’s recently approved hcv treatment regimen. in addition, enanta has a preclinical program in non-alcoholic steatohepatitis, or nash, which is a condition that results in liver inflammation and damage caused by a buildup of fat in the liver. enanta pharmaceuticals is a public company with offices in watertown, ma.

Complete history of Mr. Gardiner stock trades at Enanta Pharmaceuticals Inc

Enanta Pharmaceuticals Inc executives and stock owners

Enanta Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Jay Luly,
  President, Chief Executive Officer, Director
• Yat Sun Or,
  Senior Vice President - Research & Development, Chief Scientific Officer
• Nathalie Adda,
  Senior Vice President and Chief Medical Officer
• Paul Mellett,
  Chief Financial Officer, Senior Vice President - Finance & Administration
• Nathaniel Gardiner,
  Senior Vice President, General Counsel
• Dr. Jay R. Luly,
  Pres, CEO & Director
• Dr. Yat Sun Or,
  Sr. VP of R&D and Chief Scientific Officer
• Dr. Nathalie Adda,
  Sr. VP & Chief Medical Officer
• Nathaniel S. Gardiner J.D.,
  Sr. VP, Gen. Counsel & Sec.
• Paul J. Mellett Jr.,
  Sr. VP of Fin. & Admin. and CFO
• Bruce Carter,
  Independent Non-Executive Chairman of the Board
• Terry Vance,
  Independent Director
• George Golumbeski,
  Independent Director
• Lesley Russell,
  Independent Director
• Kristine Peterson,
  Independent Director
• Mark Foletta,
  Independent Director
• Carol Miceli,
  Director, Investor Relations
• Brendan Luu,
  Sr. VP of Bus. Devel.
• Tara Lynn Kieffer Ph.D.,
  Sr. VP of New Product Strategy & Devel.
• Jennifer Viera,
  Sr. Director of Investor Relations & Corp. Communications
• Ernst Guenter Afting,
  Director
• Tim Ocain,
  Senior Vice President
• Stephen Jr. Buckley,
  Director
• V Life Science Ventures Gmb...,
  
• V Life Science Ventures Gmb...,
  
• Helmut Schuhsler,
  Director
• David Poorvin,
  Director
• Capital Granite, L.P.M Rna ...,
  
• Marc E. Goldberg,
  Director
• Gregory L. Verdine,
  Director
• & Co Ltd Shionogi,
  10% owner
• Yujiro S Hata,
  Director
• Brendan Luu,
  Chief Business Officer
• Scott T. Rottinghaus,
  Chief Medical Officer
• Tara Lynn Kieffer,
  Chief Product Strategy Officer
• Matthew Paul Kowalsky,
  Chief Legal Officer